We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Stem Cell Therapy Cures Friedreich's Ataxia in Mouse Model

By LabMedica International staff writers
Posted on 09 Nov 2017
Stem cell therapy was used to cure Friedreich's ataxia in a mouse model of the fatal degenerative disease.

Friedreich’s ataxia (FRDA) is an incurable autosomal recessive neurodegenerative disease caused by reduced expression of the mitochondrial protein frataxin due to a mutation that causes repetition of the GAA nucleotide segment of the FXN gene. More...
Reduced frataxin levels cause a degenerative neuromuscular disorder that initially impairs motor function, such as gait and coordination, but can lead to scoliosis, heart disease, vision loss, and diabetes. While cognitive function is not affected, the disease is progressively debilitating, and ultimately requires full-time use of a wheelchair. Currently there is no treatment for FRDA.

Investigators at the University of California, San Diego (USA) worked with the YG8R mouse model that closely approximates human FRDA. This transgenic mouse model expresses two mutant human FXN transgenes, and the animals exhibit the resulting progressive neurological degeneration and muscle weakness.

The investigators treated the YG8R mice with a single injection of wild-type mouse hematopoietic stem and progenitor cells (HSPCs).

They reported in the October 25, 2017, online edition of the journal Science Translational Medicine that transplanted HSPCs engrafted and then differentiated into microglia in the brain and spinal cord and into macrophages in the dorsal root ganglia, heart, and muscle of the YG8R FRDA mice.

The therapy induced transfer of wild-type frataxin and Cox8 mitochondrial proteins from HSPC-derived microglia/macrophages to FRDA mouse neurons and muscle myocytes. The treatment prevented development of muscle weakness and locomotor deficits as well as degeneration of large sensory neurons in the dorsal root ganglia. Mitochondrial capacity was improved in brain, skeletal muscle, and heart.

"Transplantation of wildtype mouse HSPCs essentially rescued FRDA-impacted cells," said senior author Dr. Stephanie Cherqui, associate professor of pediatrics at the University of California, San Diego. "Frataxin expression was restored. Mitochondrial function in the brains of the transgenic mice normalized, as did in the heart. There was also decreased skeletal muscle atrophy."

Related Links:
University of California, San Diego


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.